The U.S. Food and Drug Administration (FDA) has cleared Avenda Health's iQuest platform for use in prostate cancer management.
iQuest combines existing patient-specific diagnostic information and deep-learning algorithms to create a tailored map of where cancer is within the prostate. The platform enables a physician to make decisions that consider the cancer extent, rather than treating the whole organ, according to Avenda. Ultimately, the platform supports physicians and patients with treatment selection, planning, guidance, and follow-up, the company said.
In addition, Avenda noted that the company recently raised $10 million in series B funding to accelerate the use of iQuest and continue clinical evidence development.
